Terms: = Lung cancer AND EIF3E, eIF3-p46, 3646, ENSG00000104408, EIF3S6, eIF3e, EIF3-P48, INT6 AND Treatment
7 results:
1. MicroRNA miR-3646 promotes malignancy of lung adenocarcinoma cells by suppressing sorbin and SH3 domain-containing protein 1 via the c-Jun NH2-terminal kinase signaling pathway.
Wang C; Cheng B
Bioengineered; 2022 Mar; 13(3):4869-4884. PubMed ID: 35196185
[TBL] [Abstract] [Full Text] [Related]
2. Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.
Dong Y; Zhou Z; Wang J; Ma L; Liu Z; Wang Y; Song J; Zhang S; Che N
Pathol Res Pract; 2019 May; 215(5):946-951. PubMed ID: 30760406
[TBL] [Abstract] [Full Text] [Related]
3. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.
Lee J; Minden MD; Chen WC; Streck E; Chen B; Kang H; Arruda A; Ly D; Der SD; Kang S; Achita P; D'Souza C; Li Y; Childs RW; Dick JE; Zhang L
Clin Cancer Res; 2018 Jan; 24(2):370-382. PubMed ID: 29074605
[No Abstract] [Full Text] [Related]
4. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
[TBL] [Abstract] [Full Text] [Related]
5. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Liu S; Wang D; Chen B; Wang Y; Zhao W; Wu J
Lung Cancer; 2011 Aug; 73(2):203-10. PubMed ID: 21211862
[TBL] [Abstract] [Full Text] [Related]
6. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract] [Full Text] [Related]
7. The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer.
Shepherd FA; Abratt R; Crino L; Green M; Sandler A; Steward W; Iglesias J; Anglin G
Lung Cancer; 2000 Nov; 30(2):117-25. PubMed ID: 11086205
[TBL] [Abstract] [Full Text] [Related]
